Economic and clinical impact of a novel, light-based, at-home antiviral treatment on mild-to-moderate COVID-19. (31st December 2022)

• Record Type: Journal Article
• Authors: Gibson, Scott; Saunders, Rhodri; Stasko, Nathan; Bickerstaff, Cherrishe-Brown; Oakley, John; Osterman, Mark; Torres, Rafael Torrejon; Kish, Jonathan K.; Feinberg, Bruce A.; Emerson, David
• Is Part Of: Journal of medical economics. Volume 25:Number 1(2022)
• Page Start: 503
• Page End: 514
• Publication Date: 2022-12-31
• Subjects: COVID-19 -- economic model -- antiviral treatment -- health care costs -- hospitalization; I18 -- I -- E17 -- E1 -- E -- I1; Medical care -- Cost control -- Periodicals; Medical economics -- Periodicals; 362.10941
• DOI: 10.1080/13696998.2022.2055370
• Languages: English
• ISSNs: 1369-6998

Abstract

Abstract: Objectives: Antiviral treatments for early intervention in patients with mild-to-moderate COVID-19 are needed as a complement to vaccination. We sought to estimate the impact on COVID-19 cases, deaths, and direct healthcare costs over 12 months following introduction of a novel, antiviral treatment, RD-X19, a light-based, at-home intervention designed for the treatment of mild-to-moderate COVID-19 infection. Methods: A time-dependent, state transition (semi-Markov) cohort model was developed to simulate infection progression in individuals with COVID-19 in 3 US states with varying levels of vaccine uptake (Alabama, North Carolina, and Massachusetts) and at the national level between 1 June 2020 and 31 May 2021. The hypothetical cohort of patients entering the model progressed through subsequent health states after infection. Costs were assigned to each health state. Number of infections/vaccinations per day were incorporated into the model. Simulations were run to estimate outcomes (cases by severity, deaths, and direct healthcare costs) at various levels of adoption of RD-X19 (5%, 10%, 25%) in eligible infected individuals at the state and national levels and across three levels of clinical benefit based on the results from an early feasibility study of RD-X19. The clinical benefit reflects a decline in the duration of symptomatic disease by 1.2, 2.4 (base case), and 3.6 days. Results: In the base case analysis with 10% adoption, simulated infections/deaths/direct healthcare costs were reduced by 10, 059/275/$69 million in Alabama, 21, 092/545/$135 million in North Carolina, and 16, 670/415/$102 million in Massachusetts over 12 months. At the national level, 10% adoption reduced total infections/deaths/direct healthcare costs by 686, 722/17, 748/$4.41 billion. Conclusion: At-home, antiviral treatment with RD-X19 or other interventions with similar efficacy that decrease both symptomatic days and transmission probabilities can be used in concert with vaccines to reduce COVID-19 cases, deaths, and direct healthcare costs.